
Bionano Genomics (BNGO) Stock Forecast & Price Target
Bionano Genomics (BNGO) Analyst Ratings
Bulls say
Bionano Genomics reported a 7% increase in the sale of nanochannel array flowcells, reaching 8,390 in 3Q25 compared to 7,835 in the same quarter of the previous year, indicating strong demand across key geographies, including a notable expansion in Japan. The company is poised for near-term growth due to a significant 47% increase in clinical lab fee schedule payments for OGM use in hematologic malignancies and constitutional genetic disorders, which may enhance revenue streams. Management has set ambitious revenue guidance for FY2026, projecting a range of $30-33 million, reflecting a potential topline growth of up to 16% as utilization among the core customer base continues to expand.
Bears say
Bionano Genomics experienced a decline in total revenue for 4Q25, reporting $8.0 million, which represents a 2.6% year-over-year decrease, raising concerns about the company's growth trajectory. The company faces multiple risks that could hinder its financial performance, including lower-than-projected market uptake and utilization of its products, potential difficulties in securing additional capital for operations, and risks of shareholder dilution. Furthermore, a substantial net loss of $26.4 million, translating to a loss of $4.85 per share, underscores the financial challenges that could negatively impact investor confidence.
This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.
Bionano Genomics (BNGO) Analyst Forecast & Price Prediction
Start investing in Bionano Genomics (BNGO)
Order type
Buy in
Order amount
Est. shares
0 shares